Monarch Partners Asset Management LLC Arcus Biosciences, Inc. Transaction History
Monarch Partners Asset Management LLC
- $328 Million
- Q4 2022
A detailed history of Monarch Partners Asset Management LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Monarch Partners Asset Management LLC holds 58,847 shares of RCUS stock, worth $865,050. This represents 0.37% of its overall portfolio holdings.
Number of Shares
58,847
Previous 58,430
0.71%
Holding current value
$865,050
Previous $1.53 Million
20.47%
% of portfolio
0.37%
Previous 0.46%
Shares
2 transactions
Others Institutions Holding RCUS
# of Institutions
201Shares Held
51.7MCall Options Held
236KPut Options Held
141K-
Black Rock Inc. New York, NY9.76MShares$144 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.47MShares$80.4 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA3.48MShares$51.1 Million0.48% of portfolio
-
State Street Corp Boston, MA3.01MShares$44.3 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.44MShares$35.8 Million0.1% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.06B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...